ReviewTrends in endocrinology and metabolism: TEM2010
Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor.
Review in Trends in endocrinology and metabolism: TEM, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 41 citations in OpenAlex.
- Oncogenic driver and therapeutic target: Prolactin signalling axis in retroperitoneal sarcoma.Clinical and translational medicine · 2026Article
- The 20 kDa isoform of the human growth hormone variant alters adipose and muscle gene expression differently than human growth hormone.Journal of neuroendocrinology · 2025Article
- Transcription factors and hormone receptors: Sex‑specific targets for cancer therapy (Review).Oncology letters · 2025Review
- Early Investigations of 20-kDa Human Placental GH Show Promise.Endocrine, metabolic & immune disorders drug targets · 2023Article
- The Effects of 20-kDa Human Placental GH in Male and Female GH-deficient Mice: An Improved Human GH?Endocrinology · 2020Article
- From Bench to Bedside: Translating the Prolactin/Vasoinhibin Axis.Frontiers in endocrinology · 2017Review
- Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer.The oncologist · 2016Article
- Prolactin Promotes Breast Cancer Cell Migration through Actin Cytoskeleton Remodeling.Frontiers in endocrinology · 2015Article
- Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics.Orphanet journal of rare diseases · 2013Article
- Molecular mechanisms of prolactin and its receptor.Endocrine reviews · 2012Review
- Endogenous prolactin generated during peripheral inflammation contributes to thermal hyperalgesia.The European journal of neuroscience · 2011Article
- Integration of gene chip and topological network techniques to screen a candidate biomarker gene (CBG) for predication of the source water carcinogenesis risks on mouse Mus musculus.Ecotoxicology (London, England) · 2011Article
- Estrogen action and prostate cancer.Expert review of endocrinology & metabolism · 2011Article
- Lactogens and estrogens in breast cancer chemoresistance.Expert review of endocrinology & metabolism · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Breast and prostate cancers are hormone-sensitive malignancies that afflict millions of women and men. Although prolactin (PRL) is known as a survival factor that supports tumor growth and confers chemoresistance in both cancers, its precise role in these tumors has not been studied extensively. Growth hormone and placental lactogen also bind PRL receptor (PRLR) and mimic some of the actions of PRL. Blockade of the PRLR represents a novel treatment for patients with advanced breast or prostate cancer with limited therapeutic options. This review discusses different approaches for generating PRLR antagonists. Emphasis is placed on technological advances which enable high-throughput screening for small molecule inhibitors of PRLR signaling that could serve as oral medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.